Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress

<p>Newly published abstract regarding dose escalation patients provides key updates including: ≥50% PSA reduction observed across putative therapeutic dose levels ≥2.0 mg/kg – 3 of 3 in Cohort 6 (2.0 mg/kg), 2 of 3 in Cohort 7 (2.4 mg/kg) and 2 of 3 in Cohort 8 (2.88 mg/kg) No drug-related severe adverse events (SAEs) and [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/ambrx-provides-safety-and-efficacy-data-from-ongoing-phase-1-2-apex-01-trial-of-arx517-in-mcrpc-at-esmo-congress/">Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>